525 related articles for article (PubMed ID: 26944412)
21. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis.
Fujishima S; Shiomi T; Yamashita S; Yogo Y; Nakano Y; Inoue T; Nakamura M; Tasaka S; Hasegawa N; Aikawa N; Ishizaka A; Okada Y
Arch Pathol Lab Med; 2010 Aug; 134(8):1136-42. PubMed ID: 20670133
[TBL] [Abstract][Full Text] [Related]
22. MMP28 in Idiopathic Pulmonary Fibrosis: Beyond the Extracellular Matrix.
Atamas SP
Am J Respir Cell Mol Biol; 2018 Jul; 59(1):5-6. PubMed ID: 29957054
[No Abstract] [Full Text] [Related]
23. Permanent alveolar collapse is the predominant mechanism in idiopathic pulmonary fibrosis.
Todd NW; Atamas SP; Luzina IG; Galvin JR
Expert Rev Respir Med; 2015 Aug; 9(4):411-8. PubMed ID: 26165208
[TBL] [Abstract][Full Text] [Related]
24. Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions.
Xu X; Dai H; Wang C
Clin Respir J; 2016 Mar; 10(2):133-41. PubMed ID: 25047066
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases in lung diseases.
Ohbayashi H
Curr Protein Pept Sci; 2002 Aug; 3(4):409-21. PubMed ID: 12370004
[TBL] [Abstract][Full Text] [Related]
26. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.
Oruqaj G; Karnati S; Vijayan V; Kotarkonda LK; Boateng E; Zhang W; Ruppert C; Günther A; Shi W; Baumgart-Vogt E
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):E2048-57. PubMed ID: 25848047
[TBL] [Abstract][Full Text] [Related]
27. An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices.
Alsafadi HN; Staab-Weijnitz CA; Lehmann M; Lindner M; Peschel B; Königshoff M; Wagner DE
Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L896-L902. PubMed ID: 28314802
[TBL] [Abstract][Full Text] [Related]
28. Inflammation and dysregulated fibroblast proliferation--new mechanisms?
Kolb M
Sarcoidosis Vasc Diffuse Lung Dis; 2013 Sep; 30 Suppl 1():21-6. PubMed ID: 24081240
[TBL] [Abstract][Full Text] [Related]
29. Approaching the degradome in idiopathic pulmonary fibrosis.
Pardo A; Selman M; Kaminski N
Int J Biochem Cell Biol; 2008; 40(6-7):1141-55. PubMed ID: 18207447
[TBL] [Abstract][Full Text] [Related]
30. Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis.
Zhu X; Ji J; Han X
J Mol Histol; 2024 Feb; 55(1):1-13. PubMed ID: 37878112
[TBL] [Abstract][Full Text] [Related]
31. Effects of doxycycline on production of growth factors and matrix metalloproteinases in pulmonary fibrosis.
Fujita H; Sakamoto N; Ishimatsu Y; Kakugawa T; Hara S; Hara A; Amenomori M; Ishimoto H; Nagata T; Mukae H; Kohno S
Respiration; 2011; 81(5):420-30. PubMed ID: 21502778
[TBL] [Abstract][Full Text] [Related]
32. Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis.
Selman M; López-Otín C; Pardo A
Eur Respir J; 2016 Aug; 48(2):538-52. PubMed ID: 27390284
[TBL] [Abstract][Full Text] [Related]
33. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.
Ghebremariam YT; Cooke JP; Gerhart W; Griego C; Brower JB; Doyle-Eisele M; Moeller BC; Zhou Q; Ho L; de Andrade J; Raghu G; Peterson L; Rivera A; Rosen GD
J Transl Med; 2015 Aug; 13():249. PubMed ID: 26231702
[TBL] [Abstract][Full Text] [Related]
34. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
Knipe RS; Tager AM; Liao JK
Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
[TBL] [Abstract][Full Text] [Related]
35. Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis.
Wygrecka M; Kwapiszewska G; Jablonska E; von Gerlach S; Henneke I; Zakrzewicz D; Guenther A; Preissner KT; Markart P
Am J Respir Crit Care Med; 2011 Jun; 183(12):1703-14. PubMed ID: 21471103
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases.
Gueders MM; Foidart JM; Noel A; Cataldo DD
Eur J Pharmacol; 2006 Mar; 533(1-3):133-44. PubMed ID: 16487964
[TBL] [Abstract][Full Text] [Related]
37. Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis.
Bellaye PS; Kolb M
BMC Med; 2015 Sep; 13():176. PubMed ID: 26400687
[TBL] [Abstract][Full Text] [Related]
38. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model.
Selman M; Pardo A
Am J Respir Crit Care Med; 2014 May; 189(10):1161-72. PubMed ID: 24641682
[TBL] [Abstract][Full Text] [Related]
39. Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.
Hewlett JC; Kropski JA; Blackwell TS
Matrix Biol; 2018 Oct; 71-72():112-127. PubMed ID: 29625182
[TBL] [Abstract][Full Text] [Related]
40. The hedgehog system machinery controls transforming growth factor-β-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis.
Cigna N; Farrokhi Moshai E; Brayer S; Marchal-Somme J; Wémeau-Stervinou L; Fabre A; Mal H; Lesèche G; Dehoux M; Soler P; Crestani B; Mailleux AA
Am J Pathol; 2012 Dec; 181(6):2126-37. PubMed ID: 23031257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
